Nurix Therapeutics Inc (NRIX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.69B
Last updated: Nov 17, 2026 at 11:06 AM ET
Nurix Therapeutics Inc (NRIX) Competitors
The companies most similar to Nurix Therapeutics are Inhibrx Biosciences (INBX), Ultragenyx (RARE) and Innoviva (INVA). By market cap, Nurix Therapeutics ranks 6th of the 13 companies on this page; Telix Pharmaceuticals (TLX) is the largest at $3.14B.
Peer Comparison
NRIX's revenue growth of 8426.0% is above the peer median of 11.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Nurix Therapeutics (NRIX) | $1.69B | 6.4x | 2.3x | 42.0% | N/A | 8426.0% | 0.00% |
| Inhibrx Biosciences, Inc. (INBX) | $1.23B | N/A | 610.4x | 0.0% | -66.0% | -100.0% | 0.00% |
| Ultragenyx (RARE) | $1.64B | N/A | 2.2x | -71.8% | N/A | 8.1% | 0.00% |
| Innoviva Inc (INVA) | $1.35B | 5.3x | 3.0x | 44.1% | 10.8% | -1.6% | 0.00% |
| Nuvation Bio Inc (NUVB) | $1.41B | N/A | 6.7x | -67.4% | -18.7% | 242.6% | 0.00% |
| Aurinia Pharmaceuticals Inc (AUPH) | $2.11B | 15.2x | 6.4x | 97.7% | N/A | 13.9% | 0.00% |
| Structure Therapeutics Inc. American Depositary Shares (GPCR) | $1.43B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Telix Pharmaceuticals Limited (TLX) | $3.14B | N/A | 5.3x | 3.8% | -0.7% | 22.3% | 0.00% |
| Nektar Therapeutics (NKTR) | $1.27B | N/A | 23.9x | 0.0% | N/A | -20.4% | 0.00% |
| Uniqure NV (QURE) | $1.67B | N/A | 75.8x | 0.0% | -57.9% | 40.4% | 0.00% |
| Vera Therapeutics Inc (VERA) | $2.03B | N/A | 189.3x | 0.0% | -83.0% | 0.0% | 0.00% |
| Xencor Inc (XNCR) | $2.78B | N/A | 13.5x | -58.8% | -17.3% | 454.9% | 0.00% |
| Vir Biotechnology Inc (VIR) | $1.71B | N/A | 5.4x | -61.0% | N/A | 19582.0% | 0.00% |
| Peer median | $1.65B | 10.2x | 6.7x | 0.0% | -18.7% | 11.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Nurix Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Inhibrx Biosciences, Inc. (INBX) | Inhibrx, Inc., a clinical-stage biotechnology company, is focused on developing a line of new biological therapeutic candidates. | INBX competitors |
| Ultragenyx (RARE) | Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development... | RARE competitors |
| Innoviva Inc (INVA) | Innoviva, Inc. is dedicated to the development and commercialization of pharmaceutical products. The company is headquartered in Burlingame, California. | INVA competitors |
| Nuvation Bio Inc (NUVB) | Nuvation Bio Inc., a clinical-stage biopharmaceutical company, is focused on developing therapeutic candidates for oncology. | NUVB competitors |
| Aurinia Pharmaceuticals Inc (AUPH) | Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and markets therapies to treat various diseases with unmet medical needs in Japan and China. | AUPH competitors |
| Structure Therapeutics Inc. American Depositary Shares (GPCR) | Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic... | GPCR competitors |
| Telix Pharmaceuticals Limited (TLX) | Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic... | |
| Nektar Therapeutics (NKTR) | Nektar Therapeutics is a biopharmaceutical company. | NKTR competitors |
| Uniqure NV (QURE) | uniQure NV, a gene therapy company, is dedicated to developing treatments for patients suffering from genetic and other devastating diseases. | QURE competitors |
| Vera Therapeutics Inc (VERA) | Vera Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immune diseases... | VERA competitors |
| Xencor Inc (XNCR) | Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of cytokine and monoclonal antibody therapies designed... | XNCR competitors |
| Vir Biotechnology Inc (VIR) | Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. | VIR competitors |
Frequently Asked Questions About NRIX
Who are Nurix Therapeutics' main competitors?
The companies most similar to Nurix Therapeutics include Inhibrx Biosciences (INBX), Ultragenyx (RARE), Innoviva (INVA), Nuvation Bio (NUVB) and Aurinia Pharmaceuticals (AUPH), listed from the closest match.
Who is Nurix Therapeutics' biggest competitor?
Telix Pharmaceuticals (TLX) is the largest of the similar companies at $3.14B; Inhibrx Biosciences (INBX) is the closest match by business profile, size, sector and industry.
How does NRIX stock compare with its competitors?
NRIX's P/E is 6.4x against a peer median of 10.2x; its P/S is 2.3x against a peer median of 6.7x; its net margin is 42.0% against a peer median of 0.0%.
Which of Nurix Therapeutics' competitors pays a higher dividend?
Nurix Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Nurix Therapeutics bigger than its competitors?
No. Nurix Therapeutics is 6th by market cap among the 13 companies on this page; the largest is Telix Pharmaceuticals (TLX) at $3.14B.
NRIX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors